Literature DB >> 29103412

Effects of herbal extracts and compounds and pharmacological agents on pulmonary fibrosis in animal models: a review.

Hoda Mojiri-Forushani1, Ali Asghar Hemmati2, Mohammad Amin Dehghani3, Ali Reza Malayeri2, Hossein Hassan Pour3.   

Abstract

Pulmonary fibrosis, a chronic inflammatory disease that occurs mainly in older adults, is a serious health threat with few effective treatment options. The etiological aspects of pulmonary fibrosis remain unknown, though some factors such as cigarette smoking, viral infections, surfactant protein polymorphisms, and chronic or high doses use of certain drugs are considered to be risk factors for the progression of pulmonary fibrosis. No standard treatments have been introduced in clinic yet. Although glucocorticoids and antioxidant drugs have been administered, the severe and broad-spectrum adverse effects of glucocorticoids limit their use. Efforts to identify novel therapeutic agents with improved safety profiles are therefore ongoing. In this review, the authors have described the effects of herbal extracts and compounds and certain pharmacological agents on pulmonary fibrosis in animal models. These effects indicate that herbs are a promising source of compounds that can play pivotal roles in the treatment of lung fibrosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29103412     DOI: 10.1016/S2095-4964(17)60363-7

Source DB:  PubMed          Journal:  J Integr Med


  3 in total

Review 1.  Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.

Authors:  Yinghan Chan; Sachin Kumar Singh; Monica Gulati; Sheetu Wadhwa; Parteek Prasher; Deepak Kumar; Avvaru Praveen Kumar; Gaurav Gupta; Gowthamarajan Kuppusamy; Mehra Haghi; Brian Gregory George Oliver; Jon Adams; Dinesh Kumar Chellappan; Kamal Dua
Journal:  J Drug Deliv Sci Technol       Date:  2022-06-23       Impact factor: 5.062

2.  Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats via Downregulation of Related Protein and Gene Expression.

Authors:  Xuan Wang; Xia Li; Li-Na Wang; Jing-Juan Pan; Xue Yang; Yang-Lin Wei
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-28       Impact factor: 2.629

3.  Buyang Huanwu Tang inhibits cellular epithelial-to-mesenchymal transition by inhibiting TGF-β1 activation of PI3K/Akt signaling pathway in pulmonary fibrosis model in vitro.

Authors:  Zi-Fei Yin; Yang-Lin Wei; Xuan Wang; Li-Na Wang; Xia Li
Journal:  BMC Complement Med Ther       Date:  2020-01-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.